日欧米で承認されたバイオ後続品 2017年7月7日 国 …

NIHS 医薬品安全性情報 Vol.16 No.012018/0111/

Carafate’]の製品表示が改訂され， 販売名が[‘Carafate suspension’]から [‘Carafate oral suspension’]に変更さ

  Carafate

Guideline for the Development of Liposome Drug …

4 described in this document are also subject to other relevant notifications and guidelines. The active substances mentioned here include a low-molecular-weight chemical entity, a

  Molecular, Weight

Guideline for Bioequivalence Studies of Generic …

1 Guideline for Bioequivalence Studies of Generic Products for Topical Use July 7, 2003 局所皮膚適用製剤の後発医薬品のための 生物学的同等性試験ガイドライン

Since 1874 遺伝子治療用製品の開発における 国内 …

遺伝子治療の現状 海外の遺伝子治療の規制と国際調和 日本の遺伝子治療と関連規制 遺伝子治療指針の改正

Guideline for Bioequivalence Studies for Different ...

2 Section 1: Introduction This guideline describes the principles of procedures of bioequivalence studies for oral solid dosage forms that contains a different quantity of the active ingredient from an

  Guidelines, Studies, Solid, Dosage, Guideline for bioequivalence studies for, Bioequivalence, Solid dosage

Clinical Pharmacokinetic Studies of Pharmaceuticals

- 1 - Clinical Pharmacokinetic Studies of Pharmaceuticals This document is an informal translation of the official text that was promulgated in Japanese on

  Pharmaceutical, Clinical, Studies, Clinical pharmacokinetic studies of pharmaceuticals, Pharmacokinetic

平成 25 年度報告 毒物劇物指定の ... - nihs.go.jp

平成. 25 年度報告 毒物劇物指定のための有害性情報の収集・評価. 物質名： n-(2-

毒物及び劇物取締法Q＆A - nihs.go.jp

1 平成29年3月31日更新 毒物及び劇物取締法Q＆A 質問一覧 1．毒物及び劇物取締法について ..... 4

European Medicines Agency - NIHS

What is Quality Risk Management? • Proposed ICH Q9 definition: “Quality risk management is a systematic process for the identification, assessment

  Management, European, Quality, Risks, Agency, Quality risk management, Medicine, European medicines agency, Nihs, Ich q9

ICH Q9 ‘Quality Risk Management’ - NIHS

ICH Q9 ‘Quality Risk Management’ - an industry view Peter H. Gough, Eli Lilly and Company

  Management, Quality, Risks, Nihs, Ich q9 quality risk management nihs, Ich q9 quality risk management

Procedures, programs and drugs you must precertify

Procedures, programs and drugs you must precertify Participating provider precertification list Effective July 1, 2018 . Applies to. 1,2,3,4,9: Aetna

  Programs, Drug, Aetna, Procedures, Programs and drugs you

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Each mL of the solution contains 600 IU (equivalent to 44 micrograms) of follitropin alfa*. Each pre-filled pen delivers 75 IU (equivalent to 5.5 micrograms) in 0.125 mL.

  Product, Follitropin

PRODUCT INFORMATION GONAL-f PEN …

Version: A008-1116 1 Supersedes: A007-0414 PRODUCT INFORMATION GONAL-f PEN Recombinant human follicle stimulating hormone (follitropin alfa (rch))

  Anglo, Follitropin, Gonal f

ATC/DDD classification - WHO

497 WHO Drug Information Vol. 29, No. 4, 2015 ATC/DDD classification New ATC 5 th level codes, continued ATC level name/INN ATC …

  Classification, Atc ddd classification

Gonal-f - Food and Drug Administration

NDA 20-378/S-015 Page 3 Gonal-f (follitropin alfa for injection) For subcutaneous injection DESCRIPTION Gonal-f (follitropin alfa for injection) is a human follicle stimulating hormone (FSH) preparation of

  Administration, Drug, Food and drug administration, Food, Anglo, Follitropin, Gonal f

HIGH TECH LIST FEBRUARY 2017. DMA DMA NAME …

high tech list february 2017. 1 dma code dma name non-prop. name

HIGHLIGHTS OF PRESCRIBING INFORMATION …

3 FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE Follistim® AQ (follitropin beta injection) Cartridge is indicated: In Women for: 1.1 Induction of Ovulation and Pregnancy in Anovulatory Infertile Women in Whom the Cause of Infertility is Functional and Not Due to

  Follitropin, Follistim